Skip to main content
PLOS One logoLink to PLOS One
. 2022 Jul 28;17(7):e0272050. doi: 10.1371/journal.pone.0272050

LDL retention time in plasma can be -based on causation- estimated by the lipid composition of LDL and other lipoproteins

Martin Jansen 1,2,*, Christine Contini 1,2
Editor: Wen-Lung Ma3
PMCID: PMC9333322  PMID: 35901111

Abstract

Introduction

Information on LDL’s dynamic behaviour of LDL (i.e. production rate and fractional catabolic rate) are of interest if pathologies, lipid-lowering strategies or LDL-metabolism itself are investigated. Determination of these rates is costly and elaborate. Here we studied the interrelationship of LDL mass, its composition and other lipoproteins. Based on this data, we deducted information about LDL’s dynamic behaviour.

Methods

Lipoprotein profiles of n = 236 participants are evaluated. Plasma was separated by sequential ultracentrifugation into VLDL, IDL, LDL and HDL. Additionally, LDL and HDL were separated into subfractions. Stepwise multiple linear regressions were used to study LDL’s ApoB mass and lipid composition. Relying on these results and on causation, we constructed a mathematical model to estimate LDL’s retention time.

Results

The ApoB mass in LDL correlated best among all measured parameters (including corresponding lipid compositions but using no LDL-associated parameters) with the cholesterol ester content in IDL. TG/CE ratios in LDL’s subfractions were strongly correlated with the corresponding ratios in IDL and HDL. The constructed mathematical model links the TG/CE ratio of LDL and HDL to LDL’s ApoB concentration and enables a good estimate of LDL’s retention time in plasma.

Discussion

Relying on our statistic evaluations, we assume that i) the production of nascent LDL via IDL as well as ii) LDL’s prolonged retention are mapped by the TG/CE ratio in LDL subfractions. HDL’s TG/CE ratio is associated with the change in LDL’s TG/CE ratio during its retention in plasma. Our mathematical model uses this information and enables–by relying on causation- a good estimation of LDL’s retention time.

Introduction

One of the main tasks of lipoproteins is to mediate the distribution of lipids among the liver and peripheral tissues. In the fasting situation, lipoproteins are classified by their density into very low-, intermediate-, low- and high-density-lipoproteins (VLDL, IDL, LDL and HDL).

There is a strong association between lipoproteins–especially LDL- and cardiovascular risk [1]. To quantify LDL in plasma, parameters such as its cholesterol-, Apolipoprotein B-100- or particle-concentrations are determined. Further, LDL’s and HDL’s TG/CE ratio are associated with hyperlipidemia [24] and LDL’s composition and phenotype are associated to cardiovascular risk [5, 6].

Kinetic studies are necessary to access information about LDL’s dynamics, i.e. its production rate and fractional catabolic rate (FCR) [7]. Kinetic data is beneficial, if interventions to lower LDL-cholesterol are interpreted and evaluated. LDL mass depends on both the production and clearance rate of LDL, which is mostly mediated by a receptor- and to less extent by a receptor-independent-pathway [8]. In severe hypertriglyceridemia LDL clearance is increased due to stimulation of the receptor-independent-pathway [9]. Hence, kinetic measurements are necessary to clarify whether an elevated concentration of LDL-particles is caused by an impaired production- or clearance-rate. These measurements are highly elaborate in their experimental design (several time points, a bolus injection of isotopic-marked amino acids) and evaluation (determining tracer-tracee ratios via mass spectrography).

LDL’s neutral fats (triglycerides (TG) and cholesterol ester (CE)) are located in its hydrophobic core. During LDL’s retention in plasma, its CE amount is affected by Cholesterol Ester Transfer Protein (CETP) [10] and its TG amount is affected by CETP and hepatic lipase (HL) [11]. Furthermore, as LDL originates mostly from IDL [12], nascent LDL inherits its CE-load from IDL, and nascent LDL particles can enter all LDL-subfractions directly [13]. Combining those facts, we assume that is possible to obtain kinetic information about LDL by just considering the CE and TG composition of LDL, IDL and other lipoproteins.

Methods

Subjects

We used data from individuals, who can or cannot be allocated to a hyper- or hypolipoproteinaemia [14]. All subjects’ data were retrieved from previous studies [15], ongoing clinical studies, or from volunteers [16] and are approved by the Freiburg Ethics Committee. Each participant gave written consent. The study subjects were divided into a normolipidemic (NL), hypertriglyceridemic (HTG) or hypercholesteridemic (HCH) group based on their plasma TG and LDL-cholesterol as described elsewhere [15].

Experimental procedure

Lipoproteins were separated and lipids and apolipoproteins then measured as described previously [16, 17]. In short, plasma was separated via sequential ultracentrifugation into VLDL, IDL, LDL and HDL. Additionally, LDL was separated into six (LDL1-LDL6, ranging from 1.019–1.031, 1.031–1.034, 1.034–1.037, 1.040–1.044 and 1.044–1.063 g/ml, respectively) and HDL into three (HDL2b, HDL2a, HDL3) subfractions [18]. Free cholesterol (FC), CE, phospholipids (PL) and TG were measured in all fractions. Apolipoproteins A1 (ApoA1), A2 (ApoA2), B-100 (ApoB) and Lipoprotein(a) (Lp(a)) were measured in the fractions and subfractions, where a significant concentration would be expected. As described in our previous work [16], TG, FC, total cholesterol and PL were determined enzymatically via PAP-methods, and the apolipoproteins were determined applying turbidimetric methods.

Notations

Let LPx and LPyz denote the concentration of x and the molar y/z ratio in the lipoprotein fraction LP, respectively. x, y and z can either be a lipid (CE, FC, PL or TG) or an apolipoprotein (ApoA1 or ApoB).

Statistics

We performed stepwise multiple linear regression analyses with a significance threshold of p<0.05 to asses variables associated to i) LDLApoB and ii) LDL1TGCELDL6TGCE. The fit of the linear model was assessed using the coefficient of determination R2.

We include all measured concentrations as well as lipid-to-ApoB ratios in all ApoB carrying lipoproteins and TG/CE ratios in all lipoprotein fractions. To omit redundancy, we excluded ApoB and lipid concentrations of LDL and total plasma (as plasma usually consists to a great extent of LDL mass) from our analysis in case i). We also excluded the TG/CE ratios in LDL and its subfractions in case ii). We checked the distributions of all parameters before including them to avoid the usage of highly non-Gaussian distributions in the linear regression. In detail, we log-transformed variables which were tested as non-Gaussian distributed (using Kolmogorov-Smirnov test, p<0.005). Associations between parameters were examined via Spearman’s rank correlation.

Differences between groups were analysed using the Mann-Whitney-U Test.

All statistical analyses were performed using IBM SPSS version 26 (IBM SPSS Statistics; IBM Corporation, Chicago, IL).

Mathematical model

We constructed (relying on our statistic results) a mathematical model which links the retention time of LDL to LDL’s lipid composition and its underlying dynamics.

Let LDL¯TGCEt be a function displaying the mean molar TG/CE ratio of a nascent LDL particle with infinite plasma retention time t hours after its entrance in plasma. Its change in TG/CE is mediated by CETP and HL action. While CETP action enriches the TG poor LDL, HL action leads to a reduction in TG in LDL.

Let’s assume i) LDL¯TGCE0=1, hence that a nascent LDL particle has a TG/CE ratio of 1 and ii) limtLDL¯TGCEt=MinTGCE, hence the particle’s TG/CE ratio approximates an equilibrium MinTGCE1. Based on previous work, in which the underlying reactions and their properties are described and discussed [15, 17, 19] and in which experiments were performed to [15] to study the influence of CETP and LCAT on LDL’s TG and CE content, we iii) assume that the ratio LDL¯TGCE decreases exponentially during its retention. Let r be the corresponding reaction rate. This is of course a simplification, but as the true underlying reaction kinetics are not fully understood and complex (CETP seems to exchange TG between lipoproteins diffusion-like), we think modelling it as a first-order reaction is a potentially good approximation–also because, being the most natural choice, it does not increase the complexity in line with the principle of parsimony. Fig 1 visualises these assumptions.

Fig 1. Sketch of the model.

Fig 1

Black solid line: exemplary trajectory of the TG/CE ratio of a hypothetical LDL particle with infinite retention time in plasma LDL¯TGCEt. The ratio decreases exponentially with rate r. Grey line: The corresponding asymptote MinTGCE. Dashed line: the observed molar TG/CE ratio in LDL LDLTGCE, which is the mean of the TG/CE ratio of all present LDL particles.

Given assumptions i)-iii), differential equations calculus leads to the explicit representation:

LDL¯TGCEt=MinTGCE+1MinTGCEexprt (Eq 1)

Note, that the probability density function F with rate parameter μ of an exponential distribution is defined as F(t;μ) = μ∙exp(−μt), if t≥0 and F(t;μ) = 0, elsewise. Let μ (in pools per days) be the rate for the exponentially distributed clearance of LDL particles from the blood. μ represents LDL’s ApoB FCR. The observed molar ratio LDLTGCE, which represents by definition the expected value of LDL¯TGCEt, can be estimated as:

LDLTGCE=0LDL¯TGCEtFt;μdt (Eq 2)

Combining (Eq 1) and (Eq 2), it holds:

LDLTGCE=0LDL¯TGCEtμexpμtdt=μ0MinTGCE+1MinTGCEexprtexpμtdt=MinTGCE+1MinTGCEμμ+r (Eq 3)

Eventually it follows:

μμ+r=LDLTGCEMinTGCE1MinTGCE (Eq 4)

So instead of the desired rate μ, which represents LDL’s ApoB FCR, we have derived a term describing the ratio μμ+r. We have no direct information about rate r (the decrease of the TG/CE ratio in a LDL particle mediated by HL and CETP action). However, given r is independent from μ and has low variance, the derived ratio is strongly associated (non-linearly) with μ. This assumption is supported by Jansen et al., who state that HL’s influence on LDL’s phenotype in non-hypertriglyceridemic conditions is rather weak [20].

Estimating LDL’s ApoB-FCR

Considering our data, w we have no direct information about the LDLApoB-FCR. We want to use the best surrogate parameter available by taking non-kinetic measurements. Considering the literature and our own intuition, LDL-cholesterol and LDLApoB fulfil this requirement as they correlate well with the FCR [2124]. Packard et al report a linear correlation of r = −0.77 (P < 0.001, n = 20) [21]. This correlation relies on causation as assuming a constant production of LDL, it holds:

LDLApoB=ProductionofLDLLDLApoBFCR (Eq 5)

Hence, if variability in the LDLApoB-FCR rather than in production is responsible for the quantity of ApoB in LDL, LDLApoB-FCR and 1LDLApoB are strongly linearly correlated. Thus we checked the (non-parametrical) correlation between the FCR-associated parameter derived from our model μμ+r and the LDLApoB-FCR estimator 1LDLApoB derived from our data and described in this section in an additional analysis.

Results

n = 236 individuals were included in this analysis, data on n = 91 subjects were already used in a prior study [15]. 145, 27 and 64 individuals were classified as NL, HTG and HCH, respectively (Fig 2).

Fig 2. Lipoprotein characteristics.

Fig 2

Quartiles in NL (black), HTG (green) and HCH (blue). (A) ApoB in the LDL subfractions, (B) CH and TG in total and CH in lipoprotein fractions (C) TG/CE ratios in HDL, LDL and its subfractions. Statistical significance determined by Mann-Whitney-U test (*p < 0.05, **p < 0.01).

Regression analysis of LDLApoB and the ratios LDL1TGCELDL6TGCE

We performed linear stepwise multiple regression to seek the best parameters explaining LDLApoB and the ratios LDL1TGCELDL6TGCE in a linear model. In Tables 1 and 2, we displayed only the two best explanatory variables. In all our results, the first is simultaneously the best linear correlating variable and -adjusted for it- the second explanatory variable is the best linear correlating parameter. The following parameters were log-transformed, when used in linear regressions: IDLTG, IDLCE,VLDLTG, IDLTGApoB, IDLTGCE,HDL2bCE,HDL2bTG, LDLTGCE, LDLCEApoB. The parameters LP(a) and HDL2bCEApoA1 were excluded from our analysis.

Table 1. Stepwise linear multiple regression on ApoB in LDL.

explanatory
variable 1
R2 explanatory
variable 2
R2
All (n = 236) IDL CE 0.508 LDLTGApoB 0.621
Normolipidemic (n = 145) IDL CE 0.353 LDLTGApoB 0.534
Hypercholesterolemia (n = 27) IDLPLApoB 0.393 -
Hypertriglyceridemia (n = 64) IDL CE 0.570 LDLTGApoB 0.646

Stepwise multiple linear regression analysis, dependent variable:

LDLApoB (ApoB in LDL). The best two explanatory variables (if existing) are illustrated. All lipid and apolipoprotein concentrations and calculated compositions in all measured lipoprotein fractions, but LDL and its subfractions were included in the analysis. It holds in all cases: p<0.001. R2; coefficient of determination.

Table 2. Linear multiple regression on lipid composition in LDL’s subfractions.

LDL1TGCE LDL2TGCE LDL3TGCE LDL4TGCE LDL5TGCE LDL6TGCE
explanatory variable R2 explanatory variable R2 explanatory variable R2 explanatory variable R2 explanatory variable R2 explanatory variable R2
Total (n = 236) 1 IDLTGCE 0.320 HDL2bTGCE 0.468 HDL2bTGCE 0.456 HDL2bTGCE 0.371 IDLTGCE 0.292 IDLTGCE 0.406
2 HDL2bTGCE 0.569 IDLTGCE 0.613 IDLTGCE 0.588 IDLTGCE 0.545 HDLTGCE 0.564 HDLTGCE 0.540
Normolipidemic (n = 145) 1 IDLTGCE 0.375 IDLCETG 0.296 IDLTGCE 0.334 IDLTGCE 0.391 IDLTGCE 0.436 IDLTGCE 0.425
2 HDL2bTGCE 0.520 HDL2bTGCE 0.518 HDL2bTGCE 0.513 HDL2bTG 0.462 HDL2bTG 0.513 HDL2bTGCE 0.537
Hypercholesterolemia (n = 27) 1 HDL2bTGCE 0.360 HDL2bTGCE 0.663 HDL2bTGCE 0.790 HDL2bTGCE 0.699 HDL2bTGCE 0.510 IDL CE 0.410
2 HDL2aTGCE 0.757 - - IDL CE 0.769 IDL CE 0.697 HDL2bTGCE 0.651
Hypertriglyceridemia (n = 64) 1 HDL2bTGCE 0.542 HDL2bTGCE 0.677 HDL2bTGCE 0.618 HDL2bTGCE 0.677 HDLTGCE 0.790 HDLTGCE 0.523
2 IDLTGCE 0.696 - IDL TG 0.645 VLDL ApoB 0.753 HDL2aTG 0.805 IDL CE 0.567

Stepwise multiple linear regression analysis, dependent variables are the molar TG to CE ratios in the LDL subfractions LDL1TGCELDL6TGCE, repectively. The best two explanatory variables (if existing) are displayed. All lipid and apolipoprotein concentrations and calculated compositions in all measured lipoprotein fractions but TG to CE ratios in the total LDL fractions and its subfractions were included in the analysis, It holds in all cases: p<0.001. R2, coefficient of determination.

  1. LDLApoB modelled with linear regression:

The best two explanatory variables of the regression were IDLCE and LDLTGApoB (Table 1). Considering the three different subpopulations, IDLCE was the first explanatory variable in all but the HCH case.

  1. The ratios LDL1TGCELDL6TGCE modelled with linear regression:

  2. IDLTGCE and HDL2bTGCE were the two most important explanatory variables in the regression (Table 2). IDLTGCE was the best explanatory variable for LDL1TGCELDL6TGCE in the NL situation (in all cases). In the HCH situation HDL2bTGCE is the best explanatory variable for LDL1TGCELDL5TGCE, while IDLCE is the best explanatory variable for LDL6TGCE. In the HTG-case HDL2bTGCE and HDLTGCE were the best explanatory variables for LDL1TGCELDL4TGCE and LDL5TGCELDL6TGCE, respectively.

Fig 3 displays to what degree the ratios LDL1TGCELDL6TGCE can be described by a linear model given the two explanatory variable HDL2bTGCE and IDLTGCE.

Fig 3. Estimating the influence of CETP on LDL’s lipid composition.

Fig 3

The bar represents the coefficient of determination R2 of a multiple linear regression model predicting LDL1TGCELDL6TGCE using the two explanatory variables V1:IDLTGCE and V2: HDL2bTGCE in 3 subgroups. Let r2(V1) and r2(V2) be the coefficients of determination, if only V1 or V2 are used as explanatory variable in a corresponding single linear regression, respectively. Three parts contribute to R2: V1 without V2 (white, R2-r2(V2)), V2 without V1 (black, R2-r2(V2)), and V1 and V2 intersecting (dashed, r2(V1)+ r2(V2)-R2).

The mathematical model

Based on the results of the linear regressions and our previous research [15], we chose MinTGCE to be proportional to HDLTGCE, as we deduced that HDLTGCE is associated with the TG/CE ratio’s equilibrium given CETP and HL action. Note that in more than 60% of our subjects it holds HDLTGCE>LDLTGCE. Hence, to ensure that MinTGCE is lower than the lowest TG/CE ratio in LDL (which it should be by definition), we scaled HDLTGCE by 0.6. We chose 0.6, as HDLTGCE*0.6<LDLTGCE was detected in 95% of our subjects. Consequently, it holds following (Eq 4):

μμ+r=LDLTGCEHDLTGCE*0.61HDLTGCE*0.6 (Eq 6)

Table 3 displays correlations for the FCR-estimator 1LDLApoB. Parameters which correlated obviously with LDLApoB (by name: CE, FC, PL and ApoB in total plasma and LDL), were excluded. The calculated parameter ratio μμ+r correlates best with the FCR-estimator in the HCH case. In the NL case, it is the second best correlating variable after IDLCE. Only in the HTG case did IDLCE and other IDL-parameters correlate clearly better than μμ+r with the FCR-estimator. Fig 4 compares 1LDLApoB and μμ+r between all subjects and the three subgroups. Both parameter’s medians are similar, however the model parameters interquartile range is distinctly broader than the FCR-estimator’s.

Table 3. Comparison of correlations associated with 1/LDLApoB.

IDL CE μμ+r LDLTGCE HDLTGCE LDLTGApoB
All (n = 236) -0.689** 0.667** 0.474** -0.105 0.432**
NL (n = 145) -0.586** 0.581** 0.437** -0.131 0.383**
HCH (n = 27) -0.422* 0.617** 0.161 -0.287 0.233
HTG (n = 64) -0.735** 0.487** 0.458* 0.210 0.386**

Non-parametric correlation (Spearman’ rho) between 1/LDLApoB (which acts as FCR estimator) and the following parameters: IDLCE(the best scoring non-LDL parameter), LDLTGApoB (derived from linear regression, Table 1), the model parameter μμ+r,LDLTGCE and HDLTGCE (as they are part of the term μμ+r).

* p<0.05,

**p<0.001

Fig 4. LDL-FCR estimation.

Fig 4

Quartiles of the FCR estimator 1/LDLApoB (grey) and the model parameter μμ+r (black). The model parameter is normalised to the median (dotted line) of 1/LDLApoB in ‘Total’).

Discussion

The heterogeneity of the lipid profiles in our analyses covers the normal NL situation as well as the two important pathological conditions hypertriglyceridemia and hypercholesterolemia. The data used in our analyses has high resolution as not only VLDL, LDL and HDL but IDL and LDL’s and HDL’s subfractions are isolated and as besides classic lipids and apolipoproteins (such as cholesterol, ApoA1 and ApoB) we additionally measured FC, PL and ApoA2. Hence, together with the relatively high number of samples (n = 236) this data is a solid base for our analyses.

The associations described by our regression analyses (Tables 1 and 2) allow us to formulate hypotheses about causal relationships between LDL’s mass and composition and other lipoprotein-data.

LDLApoB

The results of the linear regression (Table 1) suggest that (in all cases but HCH) the ApoB mass of LDL particles depends strongly on IDLCE. This is not surprising, as IDL is the main source of LDL [12]. IDLCE might be superior to other IDL parameters like IDLApoB, as it holds information as well about IDL’s kinetic properties: A less efficient transformation of IDL to LDL leads to IDL’s longer retention time, which itself leads to CE accumulation in IDL particles (via CETP-action). Hence, IDLCE might contain information about both IDLApoB-driven LDL production and IDL’s catabolic rate, which is coupled with LDL’s FCR.

The ratio LDLTGApoB is the second explanatory variable in the linear regression in all but the HCH case. Hence, adjusted to IDLCE it contains additional information about LDL’s ApoB mass. It correlates negatively with LDLApoB. This is in accordance with the hypothesis that LDL’s prolonged retention in plasma lowers its TG content [19]. In contrast to the model of van Schalkwijk et al. [19], we considered not only delipidation by lipases like HL but also the CETP-mediated net-flux of TG to LDL. This TG net-flux depends strongly on VLDL’s and HDL’s composition and concentration [15] and is incorporated within our model by letting LDL’s TG/CE ratio drop exponentially to an asymptote, which depends on CETP-mediated TG fluxes (Fig 1).

In the HCH-case, the production loses its significance as a factor influencing LDL’s mass in plasma, as the clearance via LDL-receptor is impaired. Furthermore, IDL’s production rate is significantly lower in HCH than in NL [25]. Thus considering our data, IDLCE is not the correspondingly most significant explanatory variable, but rather IDLPLApoB.

The TG/CE ratio in LDL subfractions

Considering the explanatory variables of the linear regression in Table 2, there are two categories of variables, which are important: IDL-associated variables like IDLTGCE and IDLCEApoB and HDL-associated variables like HDL2bTGCE and HDLTGCE. The IDL-associated variables may be interpreted as the influence of LDL production and the HDL-associated variables may be interpreted as the influence of prolonged plasma retention on the TGCE ratio of LDL’s subfractions.

A linear combination of HDL2bTGCE and IDLTGCE holds a strong explanatory potential for the ratios LDL1TGCELDL6TGCE (Fig 3). In the NL group, all LDL subfractions are strongly associated with IDL, which is in line with the assumption that LDL’s ApoB FCR is higher than in non-NL individuals. The subfractions in the HCH and HTG groups are strongly associated to HDL2bTGCE, which might be caused by the prolonged retention and stronger CETP-mediated TG exchange, respectively.

Considering the HCH group, LDL5 and LDL6 seem to be transient states, while LDL3 and LDL4 seem to form a sink, concurring with the observation that ApoB accumulates in FH in the middle dense LDL fractions [26]. In the HTG situation, LDL4 and LDL5 seem to form a sink. As HTG is associated with small, dense LDL, this observation also meets one’s expectation [27].

The strong association between the densest fraction LDL6TGCE and production in all but the HTG-group is somehow surprising, as there is evidence that metabolically small dense LDL is derived out of buoyant LDL [21].

Boren et al. [28] presented a conceptual model describing the genesis and interrelationship of LDL subfractions dependent on the level of plasma TG. Consistent with our data (Fig 2) small, dense LDL accumulates if plasma TG is high. In contrast to the case where the TG level is normal or low, CETP action is important for the transformation of normal sized LDL to small, dense LDL, if plasma TG is high [28]. We also observed this trend in our analysis (Table 2 and Fig 3).

Our mathematical model

Our model-derivation uses information obtained by studying the ApoB content and lipid-composition of LDL and its subfractions. Keeping in mind that the parameter μμ+r is not derived out of IDL or LDL mass but out of the two compositional ratios HDLTGCE and LDLTGCE based on our understanding of how LDL metabolism works, the level of correlation between μμ+r and the LDL-FCR estimator 1LDLApoB (Table 3) is surprisingly high. The level of correlation is in all cases superior to the corresponding level of its components HDLTGCE and LDLTGCE (Eq 6).

A central assumption of our model is that there is a connection between HDL’s TG/CE and LDL’s TG/CE ratio: At steady state, both converge to an equilibrium due to CETP and HL action. In contrast to the relatively slow LDL metabolism, HDL reaches equilibrium in its TG/CE ratio very fast. This assumption is supported by our previous work, in which CETP’s dynamics are studied [15], and the linear regressions described in this manuscript. Therefore, it is reasonable to use HDL’s TG/CE ratio to define the corresponding equilibrium in LDL (Fig 1). This way we include HL and CETP action to our model.

The weak correlation between μμ+r and the FCR-estimator 1LDLApoB in the HTG subgroup (especially coinciding with extremely high serum TG) may be caused by

  • the impact of the strongly altered TG-associated parameter r,

  • extremely skewed LDL and HDL profiles (in composition and subfraction distribution) and the difficulty of separating HDL from LDL via ultracentrifugation—especially in individuals with very high total TG,

  • altered LDL-catabolism in severe HTG [9] and

  • the fact that we (in contrast to the NL and HCH groups) cannot expect our measurements to represent a quasi-stable state regarding TGs in LDL and HDL due to slower TG-catabolism.

  • The receptor-independent-pathway clearance of LDL has a stronger impact on total LDL clearance [9]. If it exhibits a different kinetic behaviour than the receptor-mediated clearance, it violates our model-assumptions.

A clear limitation of our study is that we did not determine the real LDLApoB-FCR, but used 1LDLApoB as substitute-parameter. The estimated kinetic data derived by our model is of course clearly inferior compared to kinetic data derived by labelling molecules with stable isotopes to create tracers in vivo.

Our statistical results provide new insights on interdependencies among the mass of LDL’s subfractions and LDL’s lipid composition and other lipoproteins. We constructed, based on these results, a parameter, which creates a link between LDL’s lipid composition and its plasma-retention time. This link between lipoprotein composition and kinetic behaviour is in our view the most important aspect of this work. Our model may be employed for interpretation and evaluating of LDL-associated interventions, if no kinetic data is available.

Supporting information

S1 Table. Underlying data.

This table holds all underlying data.

(XLSX)

S2 Table. Non-parametric correlations of 1/LDLApoB and FCR-associated parameters.

(DOCX)

Acknowledgments

The authors are grateful to Linda Centofante, Anna Schulte-Kemna and Cornelia Lorey for conducting the aforementioned studies. Furthermore, we thank Nülüfer Ödünc for technical assistance.

Data Availability

All relevant data are within the article and its Supporting Information files.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82(2):495–506. doi: 10.1161/01.cir.82.2.495 [DOI] [PubMed] [Google Scholar]
  • 2.Bagdade JD, Lane JT, Stone N, Ritter MC, Subbaiah PV. Persistent abnormalities in lipoprotein composition and cholesteryl ester transfer following lovastatin treatment. Journal of lipid research. 1990;31(7):1263–9. Epub 1990/07/01. [PubMed] [Google Scholar]
  • 3.Patsch W, Gotto AM Jr. High-density lipoprotein cholesterol, plasma triglyceride, and coronary heart disease: pathophysiology and management. Adv Pharmacol. 1995;32:375–426. Epub 1995/01/01. doi: 10.1016/s1054-3589(08)61018-2 [DOI] [PubMed] [Google Scholar]
  • 4.Deckelbaum RJ, Granot E, Oschry Y, Rose L, Eisenberg S. Plasma triglyceride determines structure-composition in low and high density lipoproteins. Arteriosclerosis. 1984;4(3):225–31. Epub 1984/05/01. doi: 10.1161/01.atv.4.3.225 [DOI] [PubMed] [Google Scholar]
  • 5.Capell WH, Zambon A, Austin MA, Brunzell JD, Hokanson JE. Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B. Arteriosclerosis, thrombosis, and vascular biology. 1996;16(8):1040–6. Epub 1996/08/01. doi: 10.1161/01.atv.16.8.1040 [DOI] [PubMed] [Google Scholar]
  • 6.Diffenderfer MR, Schaefer EJ. The composition and metabolism of large and small LDL. Current opinion in lipidology. 2014;25(3):221–6. Epub 2014/05/09. doi: 10.1097/MOL.0000000000000067 [DOI] [PubMed] [Google Scholar]
  • 7.Barrett PH, Chan DC, Watts GF. Thematic review series: patient-oriented research. Design and analysis of lipoprotein tracer kinetics studies in humans. Journal of lipid research. 2006;47(8):1607–19. doi: 10.1194/jlr.R600017-JLR200 [DOI] [PubMed] [Google Scholar]
  • 8.Sniderman AD, De Graaf J, Couture P, Williams K, Kiss RS, Watts GF. Regulation of plasma LDL: the apoB paradigm. Clin Sci (Lond). 2009;118(5):333–9. Epub 2009/11/20. doi: 10.1042/CS20090402 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Packard CJ, Boren J, Taskinen MR. Causes and Consequences of Hypertriglyceridemia. Frontiers in endocrinology. 2020;11:252. Epub 2020/06/02. doi: 10.3389/fendo.2020.00252 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Tall AR. Plasma cholesteryl ester transfer protein. Journal of lipid research. 1993;34(8):1255–74. [PubMed] [Google Scholar]
  • 11.Silbernagel G, Scharnagl H, Kleber ME, Delgado G, Stojakovic T, Laaksonen R, et al. LDL triglycerides, hepatic lipase activity, and coronary artery disease: An epidemiologic and Mendelian randomization study. Atherosclerosis. 2019;282:37–44. Epub 2019/01/28. doi: 10.1016/j.atherosclerosis.2018.12.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Sigurdsson G, Nicoll A, Lewis B. Conversion of very low density lipoprotein to low density lipoprotein. A metabolic study of apolipoprotein B kinetics in human subjects. The Journal of clinical investigation. 1975;56(6):1481–90. Epub 1975/12/01. doi: 10.1172/JCI108229 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Geiss HC, Bremer S, Barrett PH, Otto C, Parhofer KG. In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy: rebound analysis of LDL subfractions after LDL apheresis. Journal of lipid research. 2004;45(8):1459–67. Epub 2004/06/04. doi: 10.1194/jlr.M300523-JLR200 [DOI] [PubMed] [Google Scholar]
  • 14.Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T. Classification of hyperlipidaemias and hyperlipoproteinaemias. Bulletin of the World Health Organization. 1970;43(6):891–915. Epub 1970/01/01. [PMC free article] [PubMed] [Google Scholar]
  • 15.Jansen M, Puetz G, Hoffmann MM, Winkler K. A mathematical model to estimate cholesterylester transfer protein (CETP) triglycerides flux in human plasma. BMC systems biology. 2019;13(1):12. Epub 2019/01/24. doi: 10.1186/s12918-019-0679-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Jansen M, Pfaffelhuber P, Hoffmann MM, Puetz G, Winkler K. In silico modeling of the dynamics of low density lipoprotein composition via a single plasma sample. Journal of lipid research. 2016;57(5):882–93. Epub 2016/03/27. doi: 10.1194/jlr.M058446 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hubner K, Schwager T, Winkler K, Reich JG, Holzhutter HG. Computational lipidology: predicting lipoprotein density profiles in human blood plasma. PLoS computational biology. 2008;4(5):e1000079. doi: 10.1371/journal.pcbi.1000079 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Baumstark MW, Kreutz W, Berg A, Frey I, Keul J. Structure of human low-density lipoprotein subfractions, determined by X-ray small-angle scattering. Biochimica et biophysica acta. 1990;1037(1):48–57. doi: 10.1016/0167-4838(90)90100-t [DOI] [PubMed] [Google Scholar]
  • 19.van Schalkwijk DB, de Graaf AA, van Ommen B, van Bochove K, Rensen PC, Havekes LM, et al. Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size. Journal of lipid research. 2009;50(12):2398–411. doi: 10.1194/jlr.M800354-JLR200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Jansen H, Verhoeven AJ, Sijbrands EJ. Hepatic lipase: a pro- or anti-atherogenic protein? Journal of lipid research. 2002;43(9):1352–62. Epub 2002/09/18. doi: 10.1194/jlr.r200008-jlr200 [DOI] [PubMed] [Google Scholar]
  • 21.Packard CJ, Demant T, Stewart JP, Bedford D, Caslake MJ, Schwertfeger G, et al. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. Journal of lipid research. 2000;41(2):305–18. [PubMed] [Google Scholar]
  • 22.Matthan NR, Jalbert SM, Lamon-Fava S, Dolnikowski GG, Welty FK, Barrett HR, et al. TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status. Arteriosclerosis, thrombosis, and vascular biology. 2005;25(8):1691–6. Epub 2005/06/04. doi: 10.1161/01.ATV.0000172629.12846.b8 [DOI] [PubMed] [Google Scholar]
  • 23.Ng TW, Watts GF, Barrett PH, Rye KA, Chan DC. Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes care. 2007;30(11):2945–50. Epub 2007/08/10. doi: 10.2337/dc07-0768 [DOI] [PubMed] [Google Scholar]
  • 24.Robertson J, Porter D, Sattar N, Packard CJ, Caslake M, McInnes I, et al. Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Annals of the rheumatic diseases. 2017;76(11):1949–52. Epub 2017/09/17. doi: 10.1136/annrheumdis-2017-211708 [DOI] [PubMed] [Google Scholar]
  • 25.Zulewski H, Ninnis R, Miserez AR, Baumstark MW, Keller U. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100. Journal of lipid research. 1998;39(2):380–7. [PubMed] [Google Scholar]
  • 26.Schamberger BM, Geiss HC, Ritter MM, Schwandt P, Parhofer KG. Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia. Journal of lipid research. 2000;41(5):727–33. Epub 2000/04/29. [PubMed] [Google Scholar]
  • 27.Campos H, Blijlevens E, McNamara JR, Ordovas JM, Posner BM, Wilson PW, et al. LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb. 1992;12(12):1410–9. Epub 1992/12/01. doi: 10.1161/01.atv.12.12.1410 [DOI] [PubMed] [Google Scholar]
  • 28.Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European heart journal. 2020;41(24):2313–30. Epub 2020/02/14. doi: 10.1093/eurheartj/ehz962 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Table. Underlying data.

This table holds all underlying data.

(XLSX)

S2 Table. Non-parametric correlations of 1/LDLApoB and FCR-associated parameters.

(DOCX)

Data Availability Statement

All relevant data are within the article and its Supporting Information files.


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES